However, 21 % RRMM and 25 % NDMM patients did not respond to the LD and TD regimen, respectively, despite expression of CRBN protein within the myeloma cells, suggesting the possibility of mechanisms of resistance that do not involve CRBN. The gene discussed is CRBN; the disease is plasma cell myeloma.